Depression
Four New Antidepressants May Be Safer, With Fewer Side Effects
Published in Neurological Diseases and Disorders Weekly, March 23rd, 2000
Venlafaxine, nefazodone, mirtazapine, and reboxetine may be superior to traditional tricyclics and the monoamine oxidase inhibitors because they are safer and have fewer side-effects. Their pharmacological action means that they will not interact with other drug treatments; they can also be given to match patients' psychiatric profiles. For example, depressed patients with prominent symptoms of anxiety and/or agitation may benefit from treatment with nefazodone or mirtazapine; neurovegetative symptoms such as...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Neurological Diseases and Disorders Weekly
More Articles from Neurological Diseases and Disorders Weekly
- Parkinson's Disease
Pig Tissue Transplant May Improve Parkinson's Disease - Aging
Salmon Study Spawns New Insight into Human Brain Aging - Alzheimer's Disease
Study Suggests Caregivers May be Partially Responsible for AD Weight Loss - Brain Development
Scientists Map Children's Brain Development - Cardiac Arrest
Rapid Hippocampal Shrinkage Suggests Vulnerability to Global Brain Ischemia - Diagnostics
New Fluorochrome Tracers Effective at Marking Neurotoxins - More from this issue of Neurological Diseases and Disorders Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
